Milestone Pharmaceuticals (NASDAQ:MIST) PT Lowered to $5.00 at Piper Sandler

Milestone Pharmaceuticals (NASDAQ:MISTFree Report) had its price objective decreased by Piper Sandler from $6.00 to $5.00 in a research note published on Tuesday, Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Several other research analysts have also recently commented on MIST. TD Cowen reduced their target price on Milestone Pharmaceuticals from $17.00 to $9.00 and set an outperform rating for the company in a research report on Wednesday, December 27th. HC Wainwright reissued a buy rating and set a $25.00 price objective on shares of Milestone Pharmaceuticals in a report on Monday, February 26th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $11.20.

Read Our Latest Research Report on Milestone Pharmaceuticals

Milestone Pharmaceuticals Trading Up 0.7 %

Shares of Milestone Pharmaceuticals stock opened at $1.51 on Tuesday. The company’s fifty day simple moving average is $1.63 and its 200-day simple moving average is $2.38. The company has a market cap of $50.56 million, a price-to-earnings ratio of -1.09 and a beta of 1.77. The company has a current ratio of 10.45, a quick ratio of 10.45 and a debt-to-equity ratio of 1.72. Milestone Pharmaceuticals has a 1 year low of $1.33 and a 1 year high of $4.49.

Institutional Trading of Milestone Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MIST. JPMorgan Chase & Co. increased its position in Milestone Pharmaceuticals by 94.7% in the first quarter. JPMorgan Chase & Co. now owns 13,580 shares of the company’s stock worth $87,000 after purchasing an additional 6,606 shares during the period. Acadian Asset Management LLC grew its position in shares of Milestone Pharmaceuticals by 55.6% during the 1st quarter. Acadian Asset Management LLC now owns 19,270 shares of the company’s stock worth $122,000 after buying an additional 6,889 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Milestone Pharmaceuticals by 17.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 61,743 shares of the company’s stock worth $397,000 after buying an additional 9,165 shares during the period. PDT Partners LLC acquired a new position in shares of Milestone Pharmaceuticals during the 1st quarter worth about $65,000. Finally, BNP Paribas Arbitrage SA acquired a new position in shares of Milestone Pharmaceuticals during the 1st quarter worth about $25,000. 61.32% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

(Get Free Report)

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

See Also

Analyst Recommendations for Milestone Pharmaceuticals (NASDAQ:MIST)

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.